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 BACKGROUND 
I.1. Introduction 
Productivity is a measure of output per unit of input (Zhang, Bansback, & Anis, 2011). 
In health sciences, productivity loss (PL) refers to the individual’s forgone output due 
to a health issue corresponding to the reduced output compared to a healthy individual. 
Recent years have seen considerable attention towards the adoption of a societal 
perspective in health economic evaluations (Brennan, Perola, van Ommen, Riboli, & 
Consortium, 2017). The inclusion of the societal costs into health economic evaluations 
can better inform policy and health decision-makers toward maximising national social 
welfare, even if entry costs might fall outside the annual healthcare budgets (Krol & 
Brouwer, 2014). 
Non-communicable diseases (NCDs) have been recognised to be one of the major 
challenges hindering countries face in their efforts to reach their sustainable 
development goals (SDG) (Horton, 2013). NCDs are chronic conditions requiring 
prolonged, expensive treatment regimens that adversely affect national revenue, socio-
economic welfare, and economic growth, both directly (through medical and non-
medical treatment costs) and indirectly due to productivity losses of patients as well as 
their carers (Bloom et al., 2012). This has been placing increasing pressure on 
policymakers to reimburse the most cost-effective health intervention while assuring 
future societal welfare. 
While Health Technology Assessment (HTA) generally mandates a societal perspective 
for informing reimbursement and resource allocation decisions, the bulk of the health 
economic evaluations -which are building blocks of HTA- often adopt a narrow health 
system perspective. Productivity loss (PL) is simply defined as the forgone output due 
to health issues corresponding to the reduced output compared to a healthy individual, 
whether paid or unpaid (Zhang et al., 2011). The inclusion of the societal costs into 
health economic evaluations can better inform policy and health decision-makers 




annual healthcare budgets (Krol & Brouwer, 2014). Krol and Brouwer (2014) further 
demonstrated that productivity loss costs can potentially be higher than the associated 
direct medical costs. 
The Middle east north Africa (MENA) region although comprising a variation in 
income levels, yet the region as a whole is suffering from typical LMICs symptoms of 
data, experts, and evidence scarcity (Ahmed M. Soliman, 2013; Al-Aqeel, 2012; 
Hammad, 2016). Although transferability of health economic evaluations can seem like 
a simple solution for the region, yet methodological diversity, non-standardisation as 
well as the specificities of each disease are some of the factors contributing to the 
complexity of the costs’ transferability across countries. We chose to work specifically 
with the V4 given the converging local variances in income levels, reimbursement 
capacity as well as the recent experience of member countries in HTA development and 
institutionalization. We also use HTA as a proxy for the awareness level and 
progression towards the adoption of a societal perspective in reimbursement decisions. 
I.2. Objectives 
This work aims to demonstrate the socio-economic value of lost patients’ productivity 
due to NCDs and provide a reference for future utilisation and transferability of PL 
costs from the V4 into the MENA region. Using HTA as a proxy we systematically 
explore the contrast in HTA scientific output between the MENA and Central and 
Eastern Europe (CEE). Our aims bifurcated later on given specific regional needs to 
reach our transferability aim.  
Data scarcity from the MENA region dictated systematically mapping the health 
economic evidence allowing us to create a comprehensive MENA PL costs catalogue, 
facilitating assessment and transferability of PL costs. On the other hand, given the 
relative abundance of health economic research from the V4 region, we aimed to locally 
identify and rank NCDs PL impact as well as their significant PL drivers in order to be 
able to propose a simplified method for transferring PL cost estimates cross-regionally, 
utilising economic indicators corresponding to our identified PL drivers. In each of the 
chapters, I contextualise the research goals based on previous work and literature in 









 HYPOTHESES  
The following hypotheses were tested concerning each chapter’s aim in light of our 
final goals: 
- Hypothesis 1 (H1): Given the superior financial capacity in high-income 
countries, we assume that their group will comprise the highest share of full economic 
evaluations from the MENA region. (Rejected) 
- Hypothesis 2 (H2): Among the MENA studies reporting societal perspective 
costs, we assume that there is a significant association between country income groups 
and investigated ICD-10 disease groups. (Accepted) 
- Hypothesis 3 (H3):  Health status and educational level are significant 
predictors for musculoskeletal disease PL costs. (Accepted) 
- Hypothesis 4 (H4): We assume that cross-country PL cost differences are 
negligible among the V4, provided similar social and economic welfare. Hence, 
insignificant differences in PL cost estimates are expected within the region. (Accepted) 
- Hypothesis 5 (H5): We assume that incorporating the national Human 
capital index (HCI) as an adjustment factor can aid in generating more precise PL 
estimates interregionally than sole GDP/capita adjustment. (Accepted) 
- Hypothesis 6 (H6): we assume that adjusting for health expenditure (HE) as 
an adjustment factor can aid further in generating more precise international disease 
cost estimates when coupled with GDP/capita. (Rejected) 
 METHODS 
III.1. HTA BETWEEN THE MENA AND CEE: A SCOOPING ANALYSIS 
OF LOCAL RESEARCH 
Bibliometric analysis for high-quality peer-reviewed HTA research from the MENA 
and CEE using Scopus database R studio equipped with “bibliometrix” R-package was 
used to generate the scientific output per country, and SPSS 23 statistical software was 
used to test for significant SJR group mean differences.  
III.2. HEALTH ECONOMIC RESEARCH FROM THE MENA REGION 
Systematic review methodology was chosen as a regional literature analysis tool.  
MEDLINE (i.e. PubMed) was chosen as a source database, and PRISMA guidelines 
were followed in reporting our review.  Health economic publications were identified 
by devising a comprehensive keyword search criterion based on similar methodological 
studies. We included comparison Journal articles reporting original research on 
humans, involved the local population from the target MENA countries, was a full or 
partial health economic analysis were included. For data extraction and descriptives, a 
Microsoft Excel spreadsheet was prepared; the first author's name, publication year, the 
target country, funding source, income status, the health technology under evaluation, 
the type of economic evaluation, the studies' perspective, and the Scimago journal rank. 
Fisher’s exact test was used to test our first hypothesis (H1). 
III.3. PL COSTS FROM THE MENA: TOWARDS A REGIONAL PL 
CATALOUGE 
In this chapter, we identified all health economic research reporting PL costs using our 




as they reported PL costs per patient per year, or can be calculated without modelling 
or complex calculations. To complete our domain, we checked and reviewed the papers 
included in the previous three high-quality regional reviews, consolidated, and 
compiled into one database to create our comprehensive regional PL costs catalogue. 
To test our second hypothesis (H2), Fisher’s exact test was used for 2x2 tables while 
chi-squared test was used for larger tables, and Cramer V statistic was reported for 
significant associations. 
III.4. PL FACTORS IN NCD PATIENTS: A POOLED ECONOMIC 
ANALYSIS 
We started by collecting, translating, and compiling patient-level raw data on 
demographics, health-related quality of life, resource use, and productivity loss from 
eleven NCD non-interventional, cross-sectional, retrospective, COI studies conducted 
in different medical centres in Hungary between the years 2003-2015, involving the 
following eleven chronic diseases: psoriatic arthritis, benign prostatic hyperplasia 
(BPH), dementia, diabetes, epilepsy, multiple sclerosis, Parkinson’s disease, psoriasis, 
rheumatoid arthritis, schizophrenia, and systemic sclerosis. Costs were adjusted for 
each disease to reflect the value in 2018-euro rates, and indirect costs were expressed 
as a percentage of GDP per capita (PL/(GDP/capita)). ANOVA analysis was used to 
compare disease group means of lost productive hours, while Spearman’s rho was 
employed to identify significant correlations between the scale variables, and they were 
both used to test our third hypothesis (H3). Finally, four weighted linear regression 
models were built to predict significant PL drivers in our pooled sample. 
III.5. REGIONAL ESTIMATES AND TRANSFERABILITY OF 
PRODUCTIVITY LOSS COSTS OF MUSCULOSKELETAL 
DISEASE: V4 TO MENA 
In this chapter, we identify, pool, and normalise musculoskeletal disease PL costs from 
the V4 region, and we utilise the identified musculoskeletal PL cost drivers (education, 
and health) to adjust our PL estimates into the MENA region accordingly. Using our 
MENA PL catalogue as a reference, we test our musculoskeletal disease adjustments 
against Tunisia's reported absenteeism costs for musculoskeletal disease (Younes et al., 
2010), using mean absolute differences (MADs) to measure accuracy and the standard 
error (SE) of means to measure each adjustment precision. While we used ANOVA to 







IV.1. HTA BETWEEN THE MENA AND CEE: A SCOOPING ANALYSIS 
OF LOCAL RESEARCH 
 
Figure 2. Prisma flow diagram for our CEE and MENA search. 
 
 
Figure 3. CEE HTA publications by year and SJR. 
 
Figure 4. Scientific output of CEE by frequency of authors’ affiliation country. 
 
In our explorative analysis of HTA literature from the CEE and MENA regions, we 
observed that that the CEE countries have been progressing notably in the last 10 years 
while the MENA is still lagging far behind. This concludes that different health 
economic research contributions are needed for each region. Therefore, for the MENA 
region, we decided to dive deeper into the region’s health economic evaluations, their 
types, quality, and active countries to identify the gaps in societal costs reporting. For 
the CEE region, we opted to narrow our source region into the V4 provided the relative 
concentration of HTA research output from the group, in addition to their similar 
political and economic states which should contribute to minimising interregional costs 
bias. In the following two chapters (V and VI) we proceed with the mapping of MENA 






IV.2. COMPARATIVE HEALTH ECONOMIC RESEARCH FROM THE 
MENA REGION 
Our search order resulted in 2017 hits, went down to 1646 after applying English 
language and full-text filters. Screening by title/abstract resulted in 219 articles eligible 
for full-text assessment. From those, we excluded 114 articles to reach our final number 





Figure 5. Number of comparative health economic studies by publication year 









Figure 7. Number of comparative health economic studied from the MENA by 










Figure 9. Number of comparative health economic studies stratified by SJR, type 
of evaluation, and country income level. 
 
This scoping review is the largest account of comparative health economic evaluations 
for the MENA region. The 105 identified evaluations, their targeted countries, diseases, 
technologies, and methods in addition to their bibliometric properties were analysed. 
Significant growth in the publications started emerging after 2014 given that more than 
half of the evaluations were published in the past 5-6 years. A total of 145 country-
specific results were identified, of which the majority were from middle-income 
countries rather than high-income countries. Almost half of the studies were full 
economic evaluations in which the health system was the predominant perspective. The 
proportion of full economic evaluations was significantly greater in middle-income 
compared to high-income countries (Fischer's exact test, p = 0.04), leading us to reject 
our first hypothesis (reject H1). Infectious disease was the top investigated ICD-10 
disease group in the region. Differences in health economic research orientation were 
significant among income groups as the majority of studies on infectious diseases 
originated from middle-income countries. 
Public health priorities in the region as reported by The World Bank concluded almost 
two decades ago that musculoskeletal and mental disease were among the top five 
leading causes of disability in the region, yet our results show that those two disease 
groups were respectively at the 12th and 10th place among the overall studied disease 
areas in the region. Out of diverging priorities from recommendations, the importance 
of assessing NCDs' societal burden for the region can be of significant value in light of 
such specific scarcity in the region’s health economic literature. Provided the limited 
availability of indirect cost estimates, we proceed with creating a regional catalogue for 











Figure 10. Prisma flowchart for MENA PL costs identification. 
 
Figure 11. funnel chart of MENA PL cost items by type. 
 
This chapter presents the largest pooling of disease PL costs from the MENA region. 
We extracted, categorised, and mapped out the regions’ PL costs to facilitate future 
field research, and boost transferability efforts in the region. We found a significant 
association (p<0.000) between country income groups and the investigated ICD-10 
disease chapters, with a high association level (Cramer's V=0.808) leading us to accept 
our second hypothesis (accept H2). In light of reported PL costs distribution, although 
diseases of the musculoskeletal system were third in line after infectious and respiratory 
diseases in terms of reported PL costs count, yet only one study reported indirect costs 
for musculoskeletal disease from the MENA.  In such mobility limiting diseases, the 
social impact is undeniable on both the patient and the caregiver. Scarce efforts have 
been shown in the region to address musculoskeletal disease and its societal cost. Our 
review has concluded sufficient PL costs from the musculoskeletal disease chapter to 
test for our transferability hypotheses. But first, we steer our direction towards the 
identification of local significant demographic, health status, and utility factors 
impacting PL costs in an attempt to develop an understanding of PL determinants on a 





IV.4. PL FACTORS IN NCD PATIENTS: A POOLED ECONOMIC 
ANALYSIS 
Table 1. Disease-specific demographics, annual resource use, health status, 
adjusted indirect cost, and indirect cost as a percent of the total cost. 
 
Table 2. Disease-specific drivers of PL (hours lost/year) with demographics, resource 






Figure 12. indirect cost as a percent of GDP/capita for eleven NCDs in Hungary. 
 
Our results emphasise that indirect costs can comprise a large portion of the total 
economic burden of NCDs. Indirect cost as a proportion of total cost measure has 
proven to be inadequate to facilitate interregional or even intraregional transferability 
of the results as it often concludes major international discrepancies. On the other hand. 
The measure of indirect cost proportion out of the national GDP/capita was 
demonstrated to be beneficial for PL results transferability by minimising costs 
divergence. Moreover, our results concluded a significant association between health 
status (P = 0.040) and educational level (P < 0.000) with PL (accept H3), we presume 
that incorporating extra adjustment measures over and above the GDP/capita indicator 
to address local population specificities, such as the human capital index (HCI) and 
health expenditure (HE), can be beneficial in transferring PL costs between regions. 
Specifically, given that musculoskeletal diseases have been demonstrated to be one of 
the most indirect cost-intensive NCDs, we chose to test our transferability hypothesis 
using musculoskeletal disease PL costs given the disease’s significance among other 
NCDs. 
 
IV.5. REGIONAL ESTIMATES AND TRANSFERABILITY OF 
PRODUCTIVITY LOSS COSTS OF MUSCULOSKELETAL DISEASE 
Table 3. Annual PL costs per patient, means, and standard deviations stratified 
by country after normalization to reflect 2020-euro value. 





Absenteeism 3 62.0 (41.6) 
Long-term disability 1 2652.24 (na) 
Premature retirement 2 4484.7 (2896.2) 
Short-term disability 1 238.65 (na) 
Total Cost 3 4015.4 (2505.1) 
Poland 
Absenteeism 3 975.8 (188.3) 
Long-term disability 6 1130.1 (659.2) 
Short-term disability 3 198.2 (43.0) 
Total PL Cost 3 3434.1 (1347.8) 
 
 




Table 4. Tunisia's mean PL cost estimates based on the proposed five methods 
presented in 2020-euro value. 
PL cost item type 
PL hours back 
calculation 
GDP+HCI GDP Wage ratio GDP+HE 



















































Figure 14. Box plots of absenteeism MADs for each adjustment method. The y-
axis represents the cost difference between our methods estimates 
and Tunisia's reference value. 
 
In this chapter, we provided a V4 regional average for PL costs stratified by type and 
normalised to reflect 2020-euro value. We also confirmed that country differences in 
normalised PL cost estimates are probably negligible within the same region accepting 
our fourth hypothesis (accept H4). Cross-regionally; we demonstrated the superiority 
of GDP-based adjustments (M2, M3, and M5) compared to wage-based adjustment 
methods (M1 and M4) in PL costs transferability. We also showed the usefulness of the 
HCI in contributing to the increased precision of transferred PL cost estimates using 
the GDP-based method (accept H5). We finally showed that using the health 
expenditure as an additional adjustment factor results in an insignificant increase in PL 
estimates accuracy at the expense of lowering precision (reject H6), rendering the 





 CONCLUSIONS AND PRACTICAL IMPLICATIONS 
Our work has identified several key findings and practical implications for the MENA, 
V4, and regional PL costs transferability while our hypotheses results shed light on 
common domains and helped steer the research direction. We found that HTA is a 
scarcely addressed topic in the MENA region, and any valid efforts in building the field 
are of great value. Data and expertise scarcity are key limiting factors in HTA research 
growth as demonstrated by the low number of publications and authors in the field. On 
the other hand, and although the CEE is in better shape, yet the local scientific output 
comprises less than half of the total regional HTA scientific output, suggesting that 
international collaborations with more advanced health systems are still fairly active in 
contributing to knowledge transfer into the CEE region. A similar approach of 
knowledge sharing can be beneficial to seed HTA efforts in the MENA. 
 
Our MENA scoping review of health economic evaluations identified and categorised 
the comparative research in the region facilitating future inter- and intraregional HTA 
collaborations based on mutual interest domains. We saw that NCDs 
underrepresentation among the region’s health economic research was significant, 
which was probably due to the much larger attention to infectious and respiratory 
diseases, in light of limited local expertise. We also noticed that the journal rank is not 
necessarily a good indicator of an evaluation’s quality, as sub-standardised evaluations 
may be published in response to the region’s research scarcity. Health economists 
should pay attention to the accuracy and usability of these results. Funding was a major 
setback in the region as almost half of the evaluations were either non-funded, or no 
funding statement was mentioned. Periodic, targeted funding and local capacity 
building are keys to vitalise the region’s health economic base. 
 
Productivity loss significance in social welfare was demonstrated in both regions. 
Mental and musculoskeletal diseases were the highest consumers of patients’ 
productivity restricting as high as 70% of the patient’s economic productive capacity 
as shown in our Hungarian NCD patient population. Education and health-related 
quality of life were of great significance in predicting PL costs, while hospital 
admissions showed to be the most cost-intensive utility in NCD management. Policies 
ensuring early started effective treatments, and targeted budget allocations for high PL 
NCDs are ought to yield significant socioeconomic returns in the medium and long 
term. 
 
Our updated V4 regional average for musculoskeletal disease PL costs provides a more 
complete picture of the societal burden of musculoskeletal disease in the V4 region, as 
close to none of the identified studies reported all patient-related PL cost types (i.e. 
mortality, absenteeism, presenteeism, early retirement, short and long term disability). 
Except for presenteeism, a normalised estimate was reported for each type of PL costs 
separately to be used as a quick-updated guide for policymakers from the V4 in 
attaining a more complete picture of the monetary impact of musculoskeletal disease 
PL within their jurisdictions. 
 
For PL costs transferability, health economists are advised to adopt a balanced pooling 
approach rather than utilising costs from a single study. Furthermore, disregarding the 
underlying methodological and theoretical aspects of the studies can lead to 
misinformed policy decisions. Ensuring that the pooling is done for similar 
methodological studies is crucial in attaining precise PL estimates. Moreover, and 
provided the significant global discrepancies in average human capital output, fine 
tweaking the transferred PL costs as per the projected national human capital output 
can provide more precise estimates for policymakers in other parts of the world. 
Adjusting for GDP and HCI combined, can significantly contribute to increasing the 
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